A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2010-09-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Mild to moderate Alzheimer's disease (MMSE 14-26)

• Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed)

Exclusion Criteria:

• Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine within 12 weeks of the start of the study

• Significant cardiovascular disease in the past 6 months

• Illness other than Alzheimer's disease that could contribute to cognitive impairment

• History of stroke or seizure disorder